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LINES OF COMMUNICATION: ADVANCES IN STEM CELL
POLICY1
DENA DAVIS, J.D., PH. D.
DEBRA GREGA, PH. D.
MR. STEIGER:
Now I think we're going to be introducing our speakers, Professors Davis and
Grega. As a bioethicist and legal scholar, Professor Dena Davis has been the
recipient of prestigious grants, fellowships and visiting scholar appointments. She
has published over 50 articles in the area of law and medicine -- from cloning to
genetic engineering -- and has lectured and taught at universities and biomedical
research institutions around the globe. She is the author, most recently, of Genetic
Dilemmas: Reproductive Technology, Parental Choices and Children's Futures.
Dr. Davis holds an adjunct appointment at Case Western Reserve University's
Department of Biomedical Ethics, and is a faculty associate in CWRU's Center for
Genetic Research Ethics and Law. She is a recent appointee to the National
Institutes of Health Committee that will determine how the NIH supports stem cell
research.
I have the personal pleasure of having her for a class this semester, and I will say
that anybody who has the opportunity next semester, or at some point in the future,
should do so.
MS. BAKER:
Good evening and thank you again for coming. I'd like to introduce our other
speaker, Dr. Grega.
Dr. Grega was named CSCRM [Center for Stem Cell & Regenerative Medicine]
Executive Director in 2004. She has had a distinguished career in biomedical
research, biotechnology business development, program management, e-commerce
and global marketing. CSCRM is a multi-institutional center composed of
investigators from Northeast Ohio's major medical and biomedical research centers,
including University Hospitals, the Cleveland Clinic and Athersys, Inc. The Center
provides a comprehensive and coordinated bench to bedside approach to
regenerative medicine, including basic and clinical research programs, biomedical
and tissue engineering programs, and the development and administration of new
therapies to patients.
MR. STEIGER:
Without further adieu: Dr. Debra Grega.
1

This is a transcription of the Journal of Law and Health’s Speaker Series event held on
November 17, 2009 at the Joseph W. Bartunek III Moot Court Room, Cleveland-Marshall
College of Law. Although the editors formatted the text and added headings and footnotes for
the reader's convenience, the substantive content has been preserved. Any errors that may
remain are the fault of the editors and not the original presenters.
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DR. GREGA:
Thank you very much. I want to thank the organizers for the invitation and the
opportunity to meet with this group and provide some information on the issue of
stem cells and our stem cell policy. I'm going to give a bit of an overview on the
main technical issues of stem cell work because without that it's hard to frame the
main concepts for regulatory, legal, and ethical issues for the research.
So, stem cell therapeutics has really captured the imagination of the public, in
addition to the biomedical community, because we have this opportunity for really
replacing damaged tissue as opposed to just essentially putting a Band-Aid on
damage and disease; and, as I point out here, it can be with undifferentiated cells all
the way to engineered-type cells. So, today, as I said, I'm going to give a bit of an
overview on stem cells, and then the impact on the science of therapeutics.
[I’d like to give] a very brief plug in terms of organizations that we have here in
Ohio. The NCRM, which is the National Center for Regenerative Medicine,2 is
made up of the Center for Stem Cell and Regenerative Medicine3 and the Clinical
Tissue Engineering Center;4 those two are funded by the State of Ohio Third Frontier
Program,5 and have those funds really in terms of late-stage research development
leading into clinical and commercial outputs. So, we've been quite fortunate in that
respect.
The other member of the NCRM is the Cleveland Cord Blood Center;6 it was
recently established in 2007 and provides a public bank for cord blood collection for
a nationwide network. We also participate in the Armed Forces Institute for
Regenerative Medicine,7 and that is a national consortium of institutions bringing
innovative regenerative medicine technology therapies for use with returning
military from the Iraq and Afghanistan conflicts. And so, I just point this out in
terms of local resource.
CHARACTERIZING CELLS
So, stem cells; what are they, why do people care about them? Well, stem cells
can be characterized a number of ways. They're used, and function, routinely, in
animal systems to repair the body, and they vary in type depending upon whether a
stem cell can replace an entire organism -- that's called pluripotent -- all the way
down to multipotent, which is really a stem cell that can only turn into a couple kinds
of tissues.

2

Further information on the NCRM can be found at the following website:
http://www.ncrm.us/ncrm/
3

The Stem Cell Center, http://www.thestemcellcenter.org/

4

Clinical Tissue Engineering Center, http://www.ctecohio.org/

5

Ohio Third Frontier, http://thirdfrontier.com/

6

Cleveland Cord Blood Center, http://www.clevelandcordblood.org/

7

This organization was formed by the Department of Defense in 2008. Further
information can be found at: http://www.defense.gov/releases/release.aspx?releaseid=11842.
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Another way to classify stem cells is based on where you're getting those cells
from. Are you obtaining them from an embryonic or an adult source? Embryonic
stem cells can come in different flavors, also. The classifications, generally -- as I've
put on the slide -- the one that is most controversial I've listed first, in terms of cells
that are derived from a fertilized egg; it's a 5-day old embryo. You can also obtain
embryonic stem cells from an egg that is unfertilized that's been manipulated, and
that's with somatic cell nuclear transfer, and I'll explain a little more about that in a
few minutes.
You can also obtain embryonic stem cells from late-stage embryos and fetuses,
which is done in a variety of locations around the world. Finally you can also obtain
embryonic-like stem cells from reprogrammed adult cells via a technology called
induced pluripotency, and I'll explain a little bit more about that in a few minutes.
Adult cells, stem cells, are cells that are obtained from any organism, any animal,
after birth. The source can be the bone marrow or many other tissues. Most people
have heard about bone marrow transplantation in terms of cancer treatments. Adult
stem cells also include umbilical-cord-derived stem cells because the baby is already
born and you're harvesting these cells from the placenta and umbilical cord.
So, what does this pluripotent terminology mean?
Well, in terms of
development, all the stem cell work really comes back to normal development. I
won't dwell on this for very long. But the blastocyst that I have in the upper right8 is
really that 5-day-old development embryo where stem cells can be isolated from. If
you let that embryo develop, it would develop along this ectoderm, mesoderm, and
endoderm lines forming different tissue types: skin and nervous system for the
ectoderm, that outer cell shell; the mesoderm, muscle and so on; and the GI tract
from the innermost layer the endoderm. When we talk about multipotent stem cells,
in general they are differentiating along these tissue lines.
EMBRYONIC CELLS
But when we talk about embryonic cells, really we're getting into the issues of
cloning. Therapeutic and reproductive cloning have stirred a lot of controversy.
And since everyone is interested in commercializing, I'm sure, at some point, we are
going to see a Friendly Frank's Cloning offering to make you new again.
Getting back to the issues on embryonic cells. As I said, you can isolate and
develop cell lines, embryonic cell lines, from a 5-day-old embryo; and that looks sort
of like this cartoon. And you take the ICM, inner cell mass, and turn it into a
perpetual cell line. The advantages of embryonic cells [are] that you can make these
lines and you can differentiate them into a variety of things. But, at this point, we
really don't have the technology to control how these cells differentiate, and that's
why at this point they're really not ready for prime time in terms of clinical utility.
We have to have a better handle on the technology, but we're moving in that
direction.
A way of forming embryonic stem cells is cloning which I have illustrated with
the diagram. For cloning purposes, I mentioned that you can do this somatic cell
nuclear transfer (SCNT). For SCNT you take an egg, take the nucleus out of the egg

8
This presentation was accompanied by a slide show that gave visual representation of
information contained herein. A time-lapse video showing an embryo reaching the blastocyst
phase can be found here: http://stemcells.nih.gov/info/cellmovie.htm.
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and replace it with a nucleus from a somatic (non-gamete) cell. So, we could make a
personalized cell line for everybody in this room by taking a skin cell, taking the
nucleus out and popping it into an egg; and then, you can coax that into developing
as if it were a fertilized egg.
If you then at the 5- to 7-day period, treat that like a fertilized egg/embryo of 5-7
days and take this inner cell mass, you can turn that into specialized cells that act like
embryonic stem cells, that are genetically identical to you, and that could turn into
any tissue. If you, instead of deriving the cell line at this point, take that blastocyst,
and put it into a surrogate mother, you could wind up with a cloned organism; Dolly
the sheep is an example of this.
And so, the difference between reproductive and therapeutic cloning is whether
you turn the cells into cell lines or whether you turn them into an organism. There
has been universal, worldwide rejection of reproductive cloning. The animals that
have been derived this way have health and genetic issues, and so it is not considered
an ethical approach in humans.
So, as I mentioned, the somatic cell nuclear transfer is swapping the old nucleus
out for the patient's nucleus. Since most folks are familiar with computers these
days, I provide this analogy: removing the nucleus of the egg = erasing your hard
drive -- so, you're essentially deleting all the programs -- if you installed a new
operating system, that is taking that nucleus from the skin cell and transplanting it in
the egg; and then, reboot the system to derive the cell lines that are of interest.
PLURIPOTENCY
Now, I mentioned yet another way to determine and to form embryonic cells, and
this is induced pluripotency. Sorry for all the science, but that's sort of -- you have to
understand it to understand some of the issues. With induced pluripotency, you just
take a somatic cell like a skin cell; and instead of manipulating the nucleus, there are
ways to coax it into thinking it's an embryonic cell. There are genes that -- it started
off with four genes, now they think there's two or three that you can use -- but
essentially take and reprogram. So, you take skin cells, reprogram them, and they
become more like embryonic stem cells; and then, you can actually, again, have a
specialized cell line that would be genetically identical into an individual.
So far, IPS [induced pluripotent stem] cells have been used in animal models.
The diagram I have here on the right is an example of the mouse that had sickle cell
anemia, they took the cells, reprogrammed them, corrected the genetic mutation for
sickle cell, then transplanted -- differentiated those embryonic genetically-modified
cells into the blood cells and gave them back to the mouse and corrected the sickle
cell anemia. So, this is another form of technology in terms of manipulating cells to
be able to have personalized medicine and personalized therapies for individuals
with genetic disorders.
ADULT STEM CELLS
A few words about adult stem cells: There's been a lot more work done on adult
cells; there are fewer ethical issues that one encounters with embryonic stem cells.
The rejection of the stem cells is not an issue if you take the stem cells from the
patient that's going to receive them. If you don't, there can be tissue-matching issues.
You've all heard about blood typing and matching tissues so you don't get tissue
rejection, like with heart or kidney transplants.
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We do have a fair amount of experience and knowledge on these adult stem cell
types, but there is technical limitations with the use of adult cells. So, what are they
currently used for? The adult cells are currently used for: treatments for cancers;
some immune disorders, like transplant rejections; bone and cartilage deficiencies
and conditions where bones don't heal; there are a number of cardiovascular trials in
terms of a heart attack (acute myocardial infarction (AMI); congestive heart failure;
limb ischemia; and also growing new blood vessels, either around the heart or in the
peripheral limbs.
There are a number stem cell trials that are currently ongoing in the United
States. You can get a survey of this if you go to clinicaltrials.gov, where they list all
of the FDA-approved trials. And again, to sort of just repeat to a certain extent some
of the information I've already given in terms of cancer, cardiovascular,
orthopaedics, and neurological disorders.
In terms of embryonic cells, there's only one clinical trial that is FDA-approved;
it is sponsored by a company, Geron,9 out of California. The cells that are used are
not strictly embryonic, per se; they have taken a human embryonic stem cell source
and differentiated it so that it is an early stage (progenitor) nervous system cell, a
support cell called a glial cell.10 This early stage glial cell is being used for the spinal
cord injury clinical trial that Geron has gotten approved by the FDA. Gerson started
the trial, but it has been stopped by the FDA due to some safety concerns. It is
anticipated that they're going to be re-starting the trial probably after the 1st of the
year.
So, hopefully the science is over and we can get on to more legal and ethical
issues. So, impact on science.
IMPACT OF POLICY ON SCIENCE
So, what kinds of policies are in place at this point in terms of the research that's
ongoing? Most people, I think, are familiar with the executive order that President
Obama issued in March of this year, and that regarding stem cell work. Prior to this
executive order, there was a restriction in terms of embryonic stem cell lines that
would be supported with federal funds. This restriction by the Bush administration
led to California instituting its own form of funding, leading to the California
Institute for Regenerative Medicine.11 And at that point, it was the 21 federally
approved lines that would be supported with federal funds.
9

Geron, http://www.geron.com/

10

A supportive cell in the central nervous system -- the brain and spinal cord. Glial cells
do not conduct electrical impulses (as opposed to neurons, which do). The glial cells surround
neurons and provide support for them and insulation between them. Glial cells are capable of
extensive signaling in response to a diversity of stimuli. Bidirectional communication exists
between glial cells and neurons, and between glial cells and vascular cells. Medical
Dictionary at MedicineNet, available at http://www.medterms.com/script/main/art.asp?
articlekey=11382.
11

The California Institute for Regenerative Medicine ("The Institute" or "CIRM") was
established in early 2005 following the passage of Proposition 71, the California Stem Cell
Research and Cures Initiative. The mission of CIRM is to support and advance stem cell
research and regenerative medicine under the highest ethical and medical standards for the
discovery and development of cures, therapies, diagnostics and research technologies to
relieve human suffering from chronic disease and injury. http://www.cirm.ca.gov/.
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In March, the funding restrictions were lifted so that federal funds can be used for
embryonic stem cell research, but there are still restrictions in terms of not permitting
the use of federal funds for cell line generation. The reason is because of the
Dickey-Wicker Amendment,12 which prohibits the use of federal funds for the
destruction of an embryo. Although there is loosening of funding in one area, there
are still restrictions in the other. Also, the other main point has been the issue of
responsible research, both in terms of science and ethics.
In terms of clinical oversight for stem cell therapies, this is really fitted into the
existing oversight processes that are in place at clinical institutions. So, there are
institutional review boards, the implementation of a new review panel on the stem
cell research oversight portion, and the continued involvement with the FDA.
IMPACT OF POLICY
So, what's been the impact? Different organizations have been trying to provide
guidance and oversight; unfortunately, nobody has the authority, so there have been
a multitude of voices on this. No one organization really has the authority to enforce
any of the guidances, if you will. The executive order that I referred to, funds
ethically derived human stem cell ES research, and so the definition of “ethicallyderived” has become a point of focus.
Many of the lines that are being used in research have an appropriate paper trail
in terms of the informed consent and materials that were used; some do not. And so,
the executive order really emphasized the provenance of the cell line and the issue of
whether it was ethically derived.
The NIH guidelines that were issued in July also emphasized responsibly-derived
human ES lines. The National Institute of Health does have some authority in terms
of what they are willing to fund, but they have no way of really reaching beyond the
restriction on the funding if they think that a line hasn't been ethically derived.
The ISSCR is the International Society for Stem Cell Research,13 so it is an
international body, not of the U.S. ISSCR has issued worldwide guidelines based on,
not only the work that's done here in the United States, but around the world: Asia,
Europe and Africa. Those are reasonable guidelines, but there is no enforcement
authority. The IASCR is the Interstate Alliance on Stem Cell Research.14 This is a
voluntary body organized by the National Academies of Science to help coordinate
state initiatives, U.S. state-level approach to human ES lines. So, it represents a
state-centric perspective.
The ISSCR and the NAS are really concerned in that there be overriding
principles that guide human ES work.
Additionally there are numerous
recommendations promoting a cell line registry so there is less ambiguity about
which lines have been ethically-derived.
12
P.L. 104-99 (Sec. 128) Prohibits any funds made available in PL 104-91 form being
used for: (1) the creation of a human embryo or embryos for research purposes; or (2) research
in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk
of injury or death greater than that allowed for research under applicable Federal regulations.
Available at http://thomas.loc.gov/cgi-bin/bdquery/z?d104:HR02880:@@@L&summ2=m&
(last visited February 11, 2010).
13

International Society for Stem Cell Research, http://www.isscr.org/.

14

Interstate Alliance on Stem Cell Research, http://www.iascr.org/.
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On the research side, as I mentioned, there are still funding restrictions in terms
of line derivation. Investigators have the ability to go to private foundations,
philanthropic or state funding sources. At many organizations, there is now stem cell
research oversight committee level of review that has been interjected into
institutional review. The issue of being more rigorous on informed consent has been
emphasized.
So, my final slide really is of -- just to review the oversight on the clinical side.
And institutions that do clinical research have institutional review boards; and so,
these IRBs are in place, obviously, to protect the rights and welfare of the human
subjects. The reach-through really has been to the individuals who may be donating
eggs for human ES line derivation. Quite frankly, it's a very complicated, technically
complex technology, in addition to the difficulty of obtaining human eggs, so there
really are only a handful of laboratories across the U.S., and really around the world,
a limited number, that actually do ES line derivation.
On the formal oversight, at the FDA the group Center for Biologics Evaluation
and Research (CBER) is responsibility for stem cell therapeutics. CBER’s prime
directive has been safety first, with ethics second. They have been trying to be
flexible in terms of developing guidelines with those proposing to conduct clinical
trials. On the actual implementation side, there's always a DSMC, which is a Data
Safety Monitoring Committee, associated with a clinical trial to review any adverse
effects.
So, with that, we can please turn this over to Dr. Davis.
DR. DAVIS:
Hi. I'd like to thank the students who put this together. And I'd also like to thank
Laura Ray and Kris Niedringhaus in the library, who helped me with slides. I always
get a panic attack when I have to do PowerPoint, which is what differentiates me
from a real scientist like Debra.
THE BEGINNINGS OF STEM CELLS
So, as Debra said: Where do we get stem cells? We can have adult stem cells,
which have few, if any, ethical problems. We have, also, the possibility of getting
them from fetal tissue. But primarily, where we would most like to get them from is
really embryos, because those are the least differentiated. I tell students, "These are
the ones who haven't declared a major." Imagine that, instead of being [generalists] - the cells in your body now are saying things like, "Oh, I only do eyelashes," or
whatever. So, what we want are cells that haven't gone down a career path; you
know, kind of still in preschool.
Where do these embryos come from? They can be IVF [In vitro fertilization]
left-overs. That's not the politically correct word, but I think that's the word that
conveys what we mean. And we now have in this country, an estimated 400,000
frozen human embryos in laboratories and clinics across the country. As you
probably know from just reading the [news] paper, when people who are having
problems with fertility need to use in vitro fertilization to make embryos, they don't
want to make just one or two at a time, because each time after you make an embryo
you need eggs and you need sperm. And to go into the woman's body every single
time every month to get an egg would be invasive, continually.
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So, what they try to do is to use hormones to have the woman make a lot of eggs
all at once, get as many eggs as possible. Maybe if you're lucky you get a dozen.
You put those in a petri dish and you put on the Frank Sinatra, you turn the lights
down and you hope that they do their thing. And then, maybe, if you're really lucky,
again, you'll have eight well-formed embryos.
Well, nobody in their right mind would put eight embryos in a woman's uterus.
So, maybe you put two in. What do you with the other six? You freeze them, right?
Maybe the couple is lucky and they complete their family and still have some left
over, maybe they give up on the procedure, maybe they get divorced. So, you end
up with a lot of frozen embryos that have been sitting around in labs for quite a
while.
You can also make embryos for research. You can ask a man and a woman to
donate their sperm and their egg. Maybe you're interested in getting embryos that
are specifically from people, both of whom carry a gene for cystic fibrosis,
something like that; and then, you will make the embryo not with the idea of
procreation, but with the idea of using it for research. And then, as Debra told us,
somatic cell nuclear transfer, which is known as cloning.
So, where are we now? Well, as Debra said, research with public funds has been
widened under President Obama, and I'm going to talk about that in a minute.
RESEARCH FUNDING
There are still sporadic attempts to criminalize research using embryonic stem
cells. If it were criminalized, then that would reach to private funding as well as
public funding. There's been research ongoing with private funds the whole time,
and that continues to happen. There's still some concern that researchers may go to
other countries where this is done more permissively; for example, in the U.K. or in
Singapore. And states such as California and New Jersey and others are starting
their own research initiatives.
Well, where are we now in the U.S. with public funds? This basically means
NIH [National Institute of Health].15 How many lines do we have? How available
are they because they're patented? Are they contaminated? Some of the older lines
were grown on mouse skin layers -- because these are living things and they need
nutrients – and that means that we probably wouldn't want to use the results of those
stem cells and put them into a human body because we'd be worried about crossspecies contamination.
What about genetic diversity? We want enough lines from enough kinds of
people that we can do research into all kinds of things that trouble the world's
population. We don't just want lines from one particular race or ethnic group. So,
effective July 7th, these are the new guidelines under the Obama administration to
resume stem cell research. And I hate people who put slides up and then read them
out loud -- like you guys can't read. Let me just tell you, if you go to nih.gov, you
will see everything you ever wanted to know. And the front page will give you a
link to policy and news and everything involving NIH and human stem cells.

15

National Institutes of Health, http://www.nih.gov/.
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REGISTRY OF STEM CELL LINES
Also, Debra spoke of a registry. And one of the things NIH is starting to do is to
put a registry on the web so that if one scientist wants to know if a particular stem
cell line is eligible for use with her NIH research money then, with a couple of clicks
of the browser, she can find out exactly what is eligible and what is not.
POST JULY 2009 CELLS
Effective last July, all human embryonic stem cells that we do research on with
public funding must be derived from embryos that were originally created for
reproduction. So, they can't be from embryos that were made for research or made
through cloning; they have to be embryos where a single woman, perhaps using a
sperm donor -- but more likely a couple came to a lab because they wanted to have
kids, and then, these embryos were left over from that process. So, the second point
is, they have to be donated by those individuals. Not necessarily the individuals who
donated the original egg. Mr. and Ms. Jones may be needing to go to a sperm donor
for the sperm, but it's Mr. and Ms. Jones who want to be parents and who go to the
clinic, and it is those people who need to give their consent.
And by the way, Debra spoke about institutional review boards. The reason this
is a research with human subjects is because of the donors, it's not because of the
embryos. So, because the donors are giving something that was originally a part of
their body, it has the same oversight as any other research with human subjects.
So, here are some guideline requirements. And basically, Section 2-A, which I'll
talk about in a minute, just tells you: If you're a scientist right now and you want to
create a line of human embryonic stem cells that can be worked with using public
money, you go to the NIH website, you look at Section 2-A, you do everything it
tells you, you write an assurance, you check off the boxes and you're done. That's
stem cells that were made after July 7th.
But there are two other categories of stem cell lines which scientists really
wanted to make sure were not left out if they didn't have to be, and one were lines
that were made in other countries. Stem cells are produced in Israel, in the U.K., in
Singapore, India, many places around the world. And we might have our American
scientists using NIH money, they might want to be part of the consortia that work on
international products. And we can't really tell Singapore or India, "Hey, you’ve got
to do it our way. This is 2-A, and you've got to toe the line." But maybe those stem
cell lines were made in the same ethical, responsible way, they just didn't exactly dot
all the Is and cross all the Ts. So, that's one category that we want to look at on a
case-by-case basis.
PRE JULY 2009 CELLS
And the second category are stem cells that were made before July of this last
summer; stem cells that, some of them were acceptable under the Bush guidelines
more than were not, they've been around for a long time, ten years or so. Some of
them are extremely interesting, extremely useful. And we didn't just want to just say,
"Well, you know, just because you didn't have the exact language of 2-A, those stem
cell lines are also unavailable."
So again, they will undergo review by a human embryonic stem cell eligibility
working group, which will then report to the ACD, which I think stands for Advisory
[Committee] to the Director of NIH. So, in the end, the decision is made by Francis
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Collins, who is the director of NIH, about what stem cell lines will or will not be
available.
So, if you were trying to go to meet Section 2-A requirements, you would do
things that really are kind of -- if you know anything about conformed consent,
research with human subjects, these things won't surprise you. You have to tell the
couple, "Here are your options if you're no longer going to use the embryos: You
can continue to freeze them, or they can be destroyed, or they can be donated to
other infertile couples," so they know all their options when they say, "Okay. You
can use them for research." You can't pay them, because that's thought to be an
undue inducement.
And you want to make sure that the couple understands that, if they say no, that
they're not going to get worse care at the clinic, and they won't be given privileged
care if they say yes. And the institution, the clinic, has to make sure that the people
who are working with the couple to help them get pregnant weren't the same people
who said, "Hey, now that you're done, can you please give us the excess embryos"
because people have all kinds of long histories and emotional involvement with the
people who tried to help them overcome infertility; and it's not the kind of, you
know, objective, arms-length relationship that you might want with somebody who's
asking you for something pretty – that carries a lot of symbolic weight.
ADDITIONAL RESEARCH
So, other kinds of research not eligible for NIH funding. Well, as Debra said,
you can't use NIH funding to derive stem cells because of the Dickey-Wicker
Amendment.16 It's kind of a funny name. I guess I'd like to say here -- this is my
only personal belief – I would like very much to overturn that amendment. Because
what that amendment says is: You can't use public money to destroy human
embryos and get their stem cells, but if somebody used private money to destroy
those embryos across the street, you can now use public money to work with those
stem cells.
And I think that's pretty hypocritical. And I think it's insulting to people who are
opposed to human embryonic stem cell research, people who are opposed to
destroying human embryos, because it suggests that they have a -- they are ethical
morons, that they think that distinction really matters; and I'd rather be clear about
where our differences are.
Other kinds of research not eligible for funding involve cloned embryos,
parthenogenesis, where you try to get eggs to kind of spontaneously grow. One
thing that's kind of interesting, though, is, you can't go to a couple who are carriers
for cystic fibrosis and say, "Hey, could you give us some sperm and eggs so that we
can make embryos with cystic fibrosis in the lab in order to destroy them?" You
can't do that with public funds.
But as you may know, people who are at risk for certain genetic diseases often
will use in vitro fertilization and something called preimplantation genetic diagnosis.
So, if you and your mate each carry the recessive gene for sickle cell or Tay-Sachs or
cystic fibrosis, what you might do is: Go to a lab and create, with a lot of luck, your
twelve embryos. And then, the lab will do -- will basically do a genetic biopsy, and
then tell you, "Well, two of these embryos have the double gene for cystic fibrosis,

16

Dickey-Wicker Amendment, supra, note 12.

2010]

LINES OF COMMUNICATION

39

and those are the ones you're not going to want to implant." And then, you might ask
the couple if they'd be willing to donate those to research. And there actually are
some lines out there that were obtained in this way, so they are specific for things
like cystic fibrosis, Huntington's disease, and so on, they offer some possibility that
we may actually be able to do something about that one of these days.
ETHICAL ISSUES
So, ethical issues real quick; you can think of them as two buckets. There are
ethical issues around embryos, and there are ethical issues around the progenitors of
those embryos. Obviously, people have enormous differences in the way they see
the moral status of human embryos, and we're not going to solve that within the next
ten minutes. I just want to point out though, that when you think about this, be a
little bit careful not to just assume that what you think about abortion is what you
think about this, because when we talk about abortion, we're talking about
terminating an embryo that was in a woman's body. And when we're talking about
these, they are extracorporeal, they're not in the woman's body and they never were;
and that may change how you think about it.
It also might be useful to know that 80 percent of 5-day-old embryos die anyway
in the process of procreation. Some people think that it's morally relevant that these
400,000 plus frozen embryos that we have now, that most of them will be discarded
at some point anyway, or they'll just hang around for 20 years and be useless. Some
people think that, therefore, we might as well not waste them, and other people think
that's a really bad argument. Some people would say that, if destroying embryos is
an evil thing in and of itself, then trying to benefit from that is complicit with that
evil. So, it's a very complicated topic, and both Bush and Obama, in their own ways,
have tried to, you know, kind of walk a line between some of those issues.
What about the progenitors, the men and women who have produced these
embryos? Well, we need informed consent, right? We're taking body tissue from
them that has enormous symbolic meaning, and they're human subjects of our
research. We don't want to coerce them. We don't want to exploit woman. As
Debra's chart showed, one of the things that you need for doing SC and T research is
an empty egg. So, where do you get those empty eggs? Women donate them. In
New York State now, they decided that it's okay to pay women for eggs. With
federal money, you can't do any of that.
Okay. That's it. So, that's an overview of some of the ethical and policy issues.
Deb and I are glad to answer questions. And again, the NIH website is just a fund of
information and great pictures and, you know, you could spend a very useful hour
there. So, thank you.
MR. STEIGER:
Thank you very much for our professors. We've got about ten minutes to take
some questions from the audience. So, anybody who has a question, please raise
your hand, we'll come around to you.
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MS. BAKER:
And, if possible, please do not speak until you have the microphone because that
will help the practice of the court reporter. This will be turned into a transcript that
we will be publishing in a later version of the Journal.
MALE 1:
Thank you very much for your remarks this evening. I just -- much of what you
said was pointed towards people who have a disease or need a corrective model. Is
any of this research dedicated towards just continuing health? Like, for instance, if I
wanted to be a contributing member of society for a thousand years.
DR. GREGA:
Although there is a lot of interest in terms of prolonging life span, that hasn't
been a major focus at this point. It's really very -MALE 1:
Just a follow up? Wouldn't that be a dramatic way to raise private funds?
DR. GREGA:
I think if the technology -- the hint on the technology side was there, you would
see that there would be companies springing up to modify your genes to be able to
promote that. That kind of work is really pretty early on. Really, on the stem-cell
side of things, it's for fixing a really discreet issue or problem, either a disease or a
damage.
MALE 1:
Thank you.
MALE 2:
My question would be: As far as the other countries that are also developing
stem cell research and things like that, and the rules and the laws that have been
created here, is it hindering our advancement, or is everybody kind of working
together? Are different nations working together to advance it as a whole, or is this
kind of a space race thing, kind of like in the '60s?
DR. DAVIS:
I'll let Debra answer part of it. But I think with the more permissive policies
now, we're going to be seeing more international cooperation, including us. If we
want to do that with public money -- and, of course, that's not the only way to
finance something -- than one of the things the working group has to ask is: Were
these responsibly created? And that means some of the things I showed before, you
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know, originally for procreation, informed consent and so on. But assuming -- so,
there are some countries -- and I won't get into trouble by naming them -- but some
countries where you worry about informed consent, and other countries, like the
U.K., where you have every reason to believe it's as rigorous as ours is.
DR. GREGA:
I do think there's a little bit of a free-for-all in terms of countries trying to
compete on this. There was, I think, a few years ago -- the research that was being
done in South Korea really caught the headlines around the world, where they were - had -- on national funding source, really promoting this. We have, I think, been
hindered in terms of national policy, but we've had states like California, New
Jersey, New York, folks in Massachusetts, with private funding being able to
compete. So, the playing field is beginning to level out.
FEMALE 1:
Have there been a lot of actual successes in the animal trials with curing these
diseases with the stem cells, like the mouse sickle cell example?
DR. GREGA:
There are a lot of examples of curing diseases in animal models. If you're a
mouse and you have cancer, boy, are you in good shape. However, it doesn't always
translate from the animal models to human. So, that's where -- generally now what
the FDA likes to see is not just the rodent model, but a large animal; and then, very
carefully, phase 1, phase 2, humans. So, there's a lot of really good animal data that
just doesn't pan out in terms of human.
MALE 1:
Thank you again. On the ethical -- and I may as well say it out loud -- slashreligious question, we saw a dramatic shift in our country from what we thought was
right wing, and now an apparent shift in the current federal administration, and there
are some people who believe there should be a law between government and
religion; but I'm just wondering how you anticipate that swinging pendulum to affect
your research. Do you see it staying in a way we can count on continuing research in
this area, or you think not?
DR. DAVIS:
That's a very complicated question because when Bush – Bush made a very
dramatic announcement in August of 2001. It was the first time that President Bush
went on television to speak to the American people, and he spoke about stem cells.
I have to say, about two months after that, I gave a stem cell 101 talk here at the
law school to my colleagues, and only one colleague knew what I was talking about.
The rest said, "Oh, thank you." So, Bush was using it as a political thing. But I don't
think most people really understood what he was talking about.
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So one question is: When does it become a convenient football -- a convenient
grandstanding or whatever? I don't think it's a separation of church and state issue.
If you really believe embryos are human, then you believe we shouldn't be killing
them, and that's no more a church/state issue than if you're opposed to the death
penalty on religious grounds. I mean, you have a right to that opinion, wherever it
stems from.
The last -- I guess the last numbers I saw were a few years ago; and, among other
things, they showed that 61 percent of American Catholics were in favor of human
embryonic stem cell research. So, the party line for a particular religious group and
what Americans actually believe are two different things.
Also, as Debra said, there's this big gap between the animal model and the
human. And we haven't seen a lot of dramatic successes yet. And one of the things
that was dispiriting about the debate -- I forget who it was who said, "If we had had - if Bush hadn't blocked stem cell research, Christopher Reeve would be alive and
walking right now," which is -- that's just totally ridiculous. So, both sides, you've
had ridiculous claims. I think once we start to see some real successes, then that will
have a political power as well.
MALE 1:
Very good. Thank you.
MR. STEIGER:
Anymore questions?
FEMALE VOICE 2:
I noticed that, in one of the slides that you showed, there was MS stem cell
research here in Cleveland. Could you tell us more about that?
DR. GREGA:
There is a clinical trial that will be starting probably at the end of quarter one
with adult-derived mesenchymal stem cells -- so, it's stem cells from the bone
marrow -- and it's utilizing the ability of these MSC -- these MSC stem cells to tone
down the immune response to the body. And since there's an immunological
component in terms of multiple sclerosis in autoimmune aspects to it, at least in the
animal model data, it has been able to show really dramatic effects.
So, the first stage on this is, that the patients will be treated with their own stem
cells; they'll be taken, isolated, and given that. But the thing that is still open is
whether those stem cells from a patient with multiple sclerosis are defective. So, the
next stage on this -- and there's animal studies ongoing right now to see if MS -these MSCs derived from MS patients are defective.
But I think -- sort of getting back to some of the issues on the implementation, I
think, in general, the -- the general population is supportive of, and is very practical,
about wanting to have effective therapies. The adult cells, I think, are going to
provide a certain transition, and will be able to address certain diseases, maybe not
all of them. And hopefully, by that point, we'll be able to backfill with embryonic
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sources that have more versatility, but we'll have more control over them, because
the issue of putting MCS cells into people and getting tumors out is really not
acceptable at this point.
MR. STEIGER:
We have time for one more question.
MALE VOICE 3:
Thanks to both of you. Dr. Grega, I thought I heard you suggest -- I thought I
heard you say that: The science has been spoken to, and now we move on to the
legal, ethical issues. Is that -- did I hear something close to that? And I wondered
what you meant by that.
DR. GREGA:
Basically I felt like I was giving too much of a science lecture to this forum. So,
I didn't mean to imply that the science is in the bag and we understand exactly what's
going on, I was just trying to promote the technical foundation for the discussion.
MR. STEIGER:
I think we're done. Thank you very much to our professors.

